博茨瓦纳接受联合抗逆转录病毒治疗的个体中低水平病毒血症的HIV-1耐药突变
在博茨瓦纳30个社区接受联合抗逆转录病毒治疗的HIV-1感染者中,分析6078条pol序列,评估单次低水平病毒血症(LLV,51-999拷贝/mL)与耐药突变及后续病毒学失败(VF,≥1000拷贝/mL)的关系。结果显示LLV者耐药突变患病率为36%,主要耐药突变为20%;随访中LLV者发生VF的OR为病毒抑制组的36倍。
要点
- 在博茨瓦纳接受联合抗逆转录病毒治疗的HIV-1感染者中,低水平病毒血症者耐药突变患病率为36%,主要耐药突变为20%。
- 单次低水平病毒血症(51-999拷贝/mL)强烈预测后续病毒学失败,OR为病毒抑制组的36倍。
- 作者建议将病毒载量>50拷贝/mL作为加强依从性支持和更频繁病毒载量监测的指征。
核心结论
- 在博茨瓦纳接受联合抗逆转录病毒治疗的成人中,单次低水平病毒血症测量强烈预测未来病毒学失败的风险,作者建议将病毒载量>50拷贝/mL作为加强依从性支持和更频繁病毒载量监测的指征。
研究设计与样本
- 研究纳入参与博茨瓦纳联合预防项目30个社区的6078名HIV-1感染者,共生成并分析6078条HIV-1 C亚型pol序列,使用斯坦福HIV耐药数据库进行解读。
- 低水平病毒血症定义为血浆病毒载量51-999拷贝/mL,病毒学失败定义为血浆病毒载量≥1000拷贝/mL。
主要发现
- 6078名HIV感染者中,4443名(73%)接受抗逆转录病毒治疗至少6个月。
- 332名接受治疗且病毒载量>50拷贝/mL者中,175名(4%)病毒载量≥1000拷贝/mL,157名(4%)为低水平病毒血症。
- 低水平病毒血症者中任何耐药突变患病率为57/157(36%),病毒载量≥1000拷贝/mL者为78/175(45%)。
- 低水平病毒血症者中主要耐药突变为31/157(20%),病毒载量≥1000拷贝/mL者为53/175(30%)(P=0.04)。
- 135名至少一种耐药突变者中,17%携带NRTI相关突变,35%携带NNRTI相关突变,6%携带PI相关突变,3%携带INSTI相关突变。
关键数值与推荐
- 低水平病毒血症定义为血浆病毒载量51-999拷贝/mL,病毒学失败定义为血浆病毒载量≥1000拷贝/mL。
- 随访的3596名参与者中,1709名(48%)入组时接受抗逆转录病毒治疗≥6个月且至少有一次后续病毒载量测量(中位随访29个月),其中43名(3%)存在低水平病毒血症。
- 入组时存在低水平病毒血症者发生病毒学失败的OR为病毒抑制组的36倍。
临床怎么用
- 作者建议将病毒载量>50拷贝/mL作为加强依从性支持和更频繁病毒载量监测的指征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether a single instance of low-level viraemia (LLV) is associated with the presence of drug resistance mutations (DRMs) and predicts subsequent virological failure (VF) in adults receiving ART in 30 communities participating in the Botswana Combination Prevention Project. METHODS: A total of 6078 HIV-1 C pol sequences were generated and analysed using the Stanford HIV drug resistance database. LLV was defined as plasma VL = 51-999 copies/mL and VF was defined as plasma VL ≥ 1000 copies/mL. RESULTS: Among 6078 people with HIV (PWH), 4443 (73%) were on ART for at least 6 months. Of the 332 persons on ART with VL > 50 copies/mL, 175 (4%) had VL ≥ 1000 copies/mL and 157 (4%) had LLV at baseline. The prevalence of any DRM was 57 (36%) and 78 (45%) in persons with LLV and VL ≥ 1000 copies/mL, respectively. Major DRMs were found in 31 (20%) with LLV and 53 (30%) with VL ≥ 1000 copies/mL (P = 0.04). Among the 135 PWH with at least one DRM, 17% had NRTI-, 35% NNRTI-, 6% PI- and 3% INSTI-associated mutations. Among the 3596 participants who were followed up, 1709 (48%) were on ART for ≥6 months at entry and had at least one subsequent VL measurement (median 29 months), 43 (3%) of whom had LLV. The OR of experiencing VF in persons with LLV at entry was 36-fold higher than in the virally suppressed group. CONCLUSIONS: A single LLV measurement while on ART strongly predicted the risk of future VF, suggesting the use of VL > 50 copies/mL as an indication for more intensive adherence support with more frequent VL monitoring.
引用
- Bareng OT, Moyo S, Zahralban-Steele M, et al. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana. J Antimicrob Chemother. 2022. PMID: 35229102. doi:10.1093/jac/dkac056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。